vimarsana.com

Latest Breaking News On - Advaite inc - Page 1 : vimarsana.com

Global COVID-19 Testing Strategic Business Report 2023: U S Market is Estimated at $5 9 Billion, While China is Forecast to Decrease by 30 7% CAGR to 2030

Test Kits Market for Corona Virus Testing Market will Decelerate at a CAGR of -4 57% through 2021-2026, Increasing the Spread Of COVID-19 Globally to Boost Growth

COVID Testing Kit Market Size to Reach USD 122,820 Million by 2030 at CAGR of 7 20% - Report by Market Research Future (MRFR)

FDA GRANTS ADVAITE EMERGENCY USE AUTHORIZATION FOR RapCov™ Rapid COVID-19 Test

Share this article Share this article MALVERN, Pa., Jan. 12, 2021 /PRNewswire/ The U.S. Food and Drug Administration has granted Emergency Use Authorization (EUA) to one of the first U.S.-manufactured serology tests designed by ADVAITE Inc., an innovative biotech company developing novel point-of-care assays to help with combatting COVID-19. The federal government s EUA for ADVAITE s rapid response IgG antibody test will strengthen America s public health protections against epidemiological threats by facilitating access to cutting-edge medical countermeasures, such as ADVAITE S RapCov™ Rapid COVID-19 Test.  ADVAITE is one of only a handful of US manufacturers to receive EUA for a point-of-care serology test.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.